Early trial tests drug combo to halt advanced cancer growth
NCT ID NCT02321501
Summary
This early-stage study aims to find the safest and most effective dose of two oral medications, ceritinib and everolimus, when used together. It involves adults with advanced solid tumors or a specific type of lung cancer (ALK-positive non-small cell lung cancer) that has spread and stopped responding to other treatments. The main goal is to understand the side effects and how well the body processes the drugs, while also looking for early signs that the combination can slow or stop tumor growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.